In June this year Europol Operation Pirates 1 took place seizing fake goods including counterfeit pharmaceuticals worth over €33m. Then between April and October another operation seized over 10.5 million medicinal products worth over €40m.
The EPO’s Enlarged Board of Appeal has issued a decision favouring patent applicants on the often tricky question of priority. This may come as a relief to US-based applicants, particularly with pre-AIA priority applications.
Healthwashing is the term used to describe the act of making a product (most frequently a food or drink) appear healthier than it is by making certain claims.
The EPO’s Board of Appeal in T0116/18 has provided welcome clarity on the application of G2/21 relating to post-filed data for inventive step.
The EU Commission published four proposals for amending the current regime for Supplementary Protection Certificates (SPCs) to enable a centralised examination of national and unitary SPCs. We summarise the proposals and some aspects of concern.
In a landmark ruling the local division of the Unified Patent Court (UPC) in Munich issued a preliminary injunction against NanoString Technologies based on European Patent 4 108 782 B1, successfully asserted by 10x Genomics and President and Fellows of Harvard College (licensee and patentee).
On 30 June 2023 the US District Court for the District of New Jersey ruled in favour of Orexo AB in its patent litigation against Sun in relation to ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (CIII), with the Court ruling that Orexo’s patents are both valid and are infringed by Sun.
In April this year, the European Commission submitted its proposals for revisions to the EU’s pharmaceutical legislation governing the authorisation of medicinal products.
The House of Lords Sub-Committee on the Protocol on Ireland/Northern Ireland released its report on the Windsor Framework on 25 July 2023. In case you missed it, we summarise below how the Framework will affect the valuable intellectual property rights known as Supplementary Protection Certificates (SPCs) in the UK.
As 10 blockbuster drug patents expire, do pharma companies need to focus even more on patent term extensions & exclusivity strategy?
Today every business is a digital business. If you don’t believe me, think about the following scenarios:
The EPO’s Enlarged Board of Appeal has attempted to clarify the law concerning the doctrine of ‘plausibility’ and the use of post-filed data to support inventive step. The questions answered are of particular relevance to those in the life science sector.
The stage is set for another referral to the Court of Justice of the EU on the eligibility criteria for Supplementary Protection Certificates for “combination products” - those comprising two or more active ingredients.
Anna has just joined Potter Clarkson this summer and Potter Clarkson’s Tom Harding sat down to chat with her at the Nordic Life Science Days conference.
In this article by Sarah Speight, Sheena Linehan has been quoted alongside the director of IP at the World Trade Organisation and the global patent head of an international law firm.